342 related articles for article (PubMed ID: 29946373)
1. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
Roulois D; Blanquart C; Panterne C; Gueugnon F; Grégoire M; Fonteneau JF
Eur J Immunol; 2012 Mar; 42(3):783-9. PubMed ID: 22144115
[TBL] [Abstract][Full Text] [Related]
3. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Leclercq S; Gueugnon F; Boutin B; Guillot F; Blanquart C; Rogel A; Padieu M; Pouliquen D; Fonteneau JF; Grégoire M
Eur Respir J; 2011 Nov; 38(5):1105-16. PubMed ID: 21540307
[TBL] [Abstract][Full Text] [Related]
4. The role of epigenetics in malignant pleural mesothelioma.
Vandermeers F; Neelature Sriramareddy S; Costa C; Hubaux R; Cosse JP; Willems L
Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315
[TBL] [Abstract][Full Text] [Related]
5. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Luszczek W; Cheriyath V; Mekhail TM; Borden EC
Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Oi S; Natsume A; Ito M; Kondo Y; Shimato S; Maeda Y; Saito K; Wakabayashi T
J Neurooncol; 2009 Mar; 92(1):15-22. PubMed ID: 19030781
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
Hurwitz JL; Stasik I; Kerr EM; Holohan C; Redmond KM; McLaughlin KM; Busacca S; Barbone D; Broaddus VC; Gray SG; O'Byrne KJ; Johnston PG; Fennell DA; Longley DB
Eur J Cancer; 2012 May; 48(7):1096-107. PubMed ID: 22154545
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Moreno-Bost A; Szmania S; Stone K; Garg T; Hoerring A; Szymonifka J; Shaughnessy J; Barlogie B; Prentice HG; van Rhee F
Cytotherapy; 2011 May; 13(5):618-28. PubMed ID: 21171821
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
12. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
13. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract][Full Text] [Related]
14. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence.
Elknerova K; Myslivcova D; Lacinova Z; Marinov I; Uherkova L; Stöckbauer P
Neoplasma; 2011; 58(1):35-44. PubMed ID: 21067264
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
[TBL] [Abstract][Full Text] [Related]
17. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
Reardon ES; Shukla V; Xi S; Gara SK; Liu Y; Straughan D; Zhang M; Hong JA; Payabyab EC; Kumari A; Richards WG; De Rienzo A; Hassan R; Miettinen M; Xi L; Raffeld M; Uechi LT; Li X; Wang R; Chen H; Hoang CD; Bueno R; Schrump DS
J Thorac Oncol; 2021 Jan; 16(1):89-103. PubMed ID: 32927122
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
[TBL] [Abstract][Full Text] [Related]
19. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.
Yi TZ; Li J; Han X; Guo J; Qu Q; Guo L; Sun HD; Tan WH
Chemotherapy; 2012; 58(1):19-29. PubMed ID: 22343305
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Paik PK; Krug LM
J Thorac Oncol; 2010 Feb; 5(2):275-9. PubMed ID: 20035240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
